HK1207796A1 - Glufosfamide combination therapies for cancer - Google Patents

Glufosfamide combination therapies for cancer Download PDF

Info

Publication number
HK1207796A1
HK1207796A1 HK15108524.1A HK15108524A HK1207796A1 HK 1207796 A1 HK1207796 A1 HK 1207796A1 HK 15108524 A HK15108524 A HK 15108524A HK 1207796 A1 HK1207796 A1 HK 1207796A1
Authority
HK
Hong Kong
Prior art keywords
cancer
combination therapies
glufosfamide
glufosfamide combination
glucose
Prior art date
Application number
HK15108524.1A
Other languages
English (en)
Chinese (zh)
Inventor
Edwin J. THOMAS
Matthew PARRIS
Forrest H. ANTHONY
Original Assignee
Eleison Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleison Pharmaceuticals LLC filed Critical Eleison Pharmaceuticals LLC
Publication of HK1207796A1 publication Critical patent/HK1207796A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15108524.1A 2012-04-19 2012-08-31 Glufosfamide combination therapies for cancer HK1207796A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261687114P 2012-04-19 2012-04-19
US61/687,114 2012-04-19
PCT/US2012/053275 WO2013158143A1 (en) 2012-04-19 2012-08-31 Glufosfamide combination therapies for cancer

Publications (1)

Publication Number Publication Date
HK1207796A1 true HK1207796A1 (en) 2016-02-12

Family

ID=49380659

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108524.1A HK1207796A1 (en) 2012-04-19 2012-08-31 Glufosfamide combination therapies for cancer

Country Status (7)

Country Link
US (1) US20130281386A1 (cg-RX-API-DMAC10.html)
EP (1) EP2846638A4 (cg-RX-API-DMAC10.html)
JP (3) JP2015514756A (cg-RX-API-DMAC10.html)
CN (1) CN104270944A (cg-RX-API-DMAC10.html)
CA (1) CA2870138A1 (cg-RX-API-DMAC10.html)
HK (1) HK1207796A1 (cg-RX-API-DMAC10.html)
WO (1) WO2013158143A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134486A1 (en) * 2015-02-27 2016-09-01 Steinberg Gregory Use of canagliflozin and derivatives thereof in the treatment of cancer
CN105030798B (zh) * 2015-06-24 2017-11-24 李宏 一种抗肿瘤的药物组合物及其制备方法和应用
EP3490543A4 (en) * 2016-08-01 2020-04-01 IC-Medtech Corp. ASCORBIC ACID, CHINONE COMPOUND AND SODIUM GLUCOSE-COTRANSPORTER INHIBITOR FOR TREATING CANCER
CN110248664B (zh) * 2017-11-28 2023-03-03 深圳艾欣达伟医药科技有限公司 葡磷酰胺的抗癌医药用途
JP7414230B2 (ja) * 2018-11-09 2024-01-16 国立大学法人 琉球大学 抗血液悪性腫瘍薬
EP3927378A1 (en) 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Method for reduction drug-induced nephrotoxicity
CN110038009B (zh) 2019-05-13 2021-01-08 浙江大学 卡格列净在制备抗肿瘤药物中的应用
KR102437311B1 (ko) * 2019-12-03 2022-09-15 주식회사 하임네이처 Ndpk 활성제 및 sglt-2 억제제를 포함하는 암의 예방 또는 치료용 약학 조성물
KR20210084919A (ko) * 2019-12-30 2021-07-08 주식회사 하임바이오 Sglt-2 억제제 및 고시폴을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
IL300847A (en) * 2020-08-26 2023-04-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Combined treatment to reduce DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289077C (en) * 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
DE19806803A1 (de) * 1998-02-18 1999-11-25 Hermann Koepsell Transporter für Saccharid-gekoppelte Zytostatika in Tumorzellen
WO2003082301A1 (en) * 2002-03-29 2003-10-09 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
KR20050111752A (ko) * 2003-03-07 2005-11-28 쓰레솔드 파마슈티컬스, 인코포레이티드 항신생물제에 의한 치료에 대한 종양의 감수성을 결정하는방법
JP2008540559A (ja) * 2005-05-11 2008-11-20 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド グルフォスファミド併用療法
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
WO2009117367A1 (en) * 2008-03-18 2009-09-24 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof

Also Published As

Publication number Publication date
CN104270944A (zh) 2015-01-07
JP2018087228A (ja) 2018-06-07
CA2870138A1 (en) 2013-10-24
WO2013158143A1 (en) 2013-10-24
US20130281386A1 (en) 2013-10-24
EP2846638A1 (en) 2015-03-18
EP2846638A4 (en) 2016-03-02
JP2020055884A (ja) 2020-04-09
JP2015514756A (ja) 2015-05-21

Similar Documents

Publication Publication Date Title
PH12016500137A1 (en) Afucosylated anti-fgfr2iiib antibodies
WO2015006740A3 (en) Oligonucleotide-ligand conjugates and process for their preparation
NZ718826A (en) Pyrrolobenzodiazepines and conjugates thereof
PT2155188E (pt) Métodos e composições para o tratamento de cancro recorrente
EA201490644A1 (ru) Терапевтические пептиды
MY188363A (en) Substituted tricyclic compounds as fgfr inhibitors
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
HK1216853A1 (zh) 治療胰腺癌的方法
WO2013119966A3 (en) Single-chain antibodies and other heteromultimers
WO2014144978A8 (en) Improved compositions for treating muscular dystrophy
MX344009B (es) Conjugados de amatoxinas con enlaces mejorados.
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
IN2015DN00255A (cg-RX-API-DMAC10.html)
WO2010078945A3 (en) Cancer treatment
MX2015005719A (es) Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
EP4582090A3 (en) Composition comprising pegylated arginine deiminase
WO2010042638A3 (en) Hpma - docetaxel or gemcitabine conjugates and uses therefore
WO2011153431A3 (en) Peripheral blood sparc antibodies and uses thereof
UA100852C2 (ru) Композиции для лечения рака
HK1214128A1 (zh) 癌症的治療
WO2008122088A8 (en) Methods for detecting a target nucleotide sequence in a sample utilising a nuclease-aptamer complex
EP3019611A4 (en) LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME
IN2014DN09830A (cg-RX-API-DMAC10.html)
WO2012078586A3 (en) Pharmaceutical composition comprising nanog shrna, and method of usnig nanog shrna to treat cancer
WO2008033887A8 (en) Methods for treating cancer